End-stage disease due to liver cirrhosis is an important cause of death worldwide. Cirrhosis results from progressive, extensive fibrosis and impaired hepatocyte regeneration. The only curative treatment is liver transplantation, but due to the several limitations of this procedure, the interest in alternative therapeutic strategies is increasing. In particular, the potential of bone marrow stem cell (BMSC) therapy in cirrhosis has been explored in different trials. In this article, we evaluate the results of 18 prospective clinical trials, and we provide a descriptive overview of recent advances in the research on hepatic regenerative medicine. The main message from the currently available data in the literature is that BMSC therapy is extremely promising in the context of liver cirrhosis. However, its application should be further explored in randomized, controlled trials with large cohorts and long follow-ups.

Bone marrow derived stem cells for the treatment of end-stage liver disease / Margini, C; Vukotic, R; Brodosi, L; Bernardi, M; Andreone, P.. - In: WORLD JOURNAL OF GASTROENTEROLOGY. - ISSN 1007-9327. - 20:(2014), pp. 9098-9105. [10.3748/wjg.v20.i27.9098]

Bone marrow derived stem cells for the treatment of end-stage liver disease

Vukotic R;Bernardi M;Andreone P.
2014

Abstract

End-stage disease due to liver cirrhosis is an important cause of death worldwide. Cirrhosis results from progressive, extensive fibrosis and impaired hepatocyte regeneration. The only curative treatment is liver transplantation, but due to the several limitations of this procedure, the interest in alternative therapeutic strategies is increasing. In particular, the potential of bone marrow stem cell (BMSC) therapy in cirrhosis has been explored in different trials. In this article, we evaluate the results of 18 prospective clinical trials, and we provide a descriptive overview of recent advances in the research on hepatic regenerative medicine. The main message from the currently available data in the literature is that BMSC therapy is extremely promising in the context of liver cirrhosis. However, its application should be further explored in randomized, controlled trials with large cohorts and long follow-ups.
20
27
9098
9105
Bone marrow derived stem cells for the treatment of end-stage liver disease / Margini, C; Vukotic, R; Brodosi, L; Bernardi, M; Andreone, P.. - In: WORLD JOURNAL OF GASTROENTEROLOGY. - ISSN 1007-9327. - 20:(2014), pp. 9098-9105. [10.3748/wjg.v20.i27.9098]
Margini, C; Vukotic, R; Brodosi, L; Bernardi, M; Andreone, P.
File in questo prodotto:
File Dimensione Formato  
Stem cells review.pdf

non disponibili

Dimensione 653.61 kB
Formato Adobe PDF
653.61 kB Adobe PDF   Visualizza/Apri   Richiedi una copia
Pubblicazioni consigliate

Caricamento pubblicazioni consigliate

Licenza Creative Commons
I metadati presenti in IRIS UNIMORE sono rilasciati con licenza Creative Commons CC0 1.0 Universal, mentre i file delle pubblicazioni sono rilasciati con licenza Attribuzione 4.0 Internazionale (CC BY 4.0), salvo diversa indicazione.
In caso di violazione di copyright, contattare Supporto Iris

Utilizza questo identificativo per citare o creare un link a questo documento: http://hdl.handle.net/11380/1237261
Citazioni
  • ???jsp.display-item.citation.pmc??? 10
  • Scopus 31
  • ???jsp.display-item.citation.isi??? 27
social impact